Comparing BTK and BCL-2 inhibitor outcomes in different CLL subgroups
Nicole Lamanna • 1 Sep 2021
Ivosidenib with venetoclax in IDH1-mutated hematological malignancies
Farhad Ravandi • 18 May 2020
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.